Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Bariatric Surgery in Children. (BASIC)

25 de agosto de 2021 atualizado por: Maastricht University Medical Center

The BASIC Trial. Morbid Obesity in Children and Adolescents: a Prospective Randomised Trial of Conservative Treatment Versus Surgery

Rationale:

In the Western world overweight and obesity is an increasing problem both in adults and in children. In youth, it is associated with early death and a number of co-morbidities including metabolic and endocrine changes, increased inflammatory status, cardiovascular abnormalities, nonalcoholic fatty liver disease, and impaired quality of life.

The standard treatment for morbid obesity in children is by combined life style interventions. However, the medium and long term effects of dietetic interventions, behaviour therapy and medication is relatively poor. In adults bariatric surgery shows good results with up to 30% weight reduction in 3 years. The preliminary results in youth are similar, but surgery in this age group is relatively uncommon. In the Netherlands surgery in this age group is only allowed in clinical trials, until the benefits and risks have been established. (National Health Authorities)

Objective:

To determine if surgery gives a superior weight and body mass index (BMI) reduction than combined life style interventions in adolescents with morbid obesity and to assess its effect on obesity associated co-morbidity.

Study design:

Prospective randomised interventional study.

Study population:

Morbidly obese children, aged 14 - 16 years, with sex and age adjusted BMI >40 kg/m2 or >35 kg/m2 with co-morbidity.

Intervention:

Bariatric surgery by laparoscopic adjustable gastric band (LAGB) or combined life style interventions

Main study parameters/endpoints:

Primary endpoints: weight loss, loss of excess weight, loss of excess BMI. Secondary endpoints: Body composition, pubertal development, metabolic and endocrine changes, inflammatory status, cardiovascular abnormalities, non-alcoholic steatohepatitis, brain development, quality of life, and behaviour changes. The potential complications of surgery are monitored.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Real)

60

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Limburg
      • Maastricht, Limburg, Holanda, 6202ZA
        • Maastricht University Medical Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

14 anos a 16 anos (Filho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Aged 14 to 16
  • Age and sex adjusted BMI >40 kg/m2 or >35 kg/m2 with associated co-morbidity.

    * Associated co-morbidity includes: glucose intolerance, type 2 diabetes, hypertension, pseudotumor cerebri, acanthosis nigricans, obstructive sleep apnoea syndrome, depression, arthropathies, non-alcoholic steatohepatitis and dyslipidemia.

  • > 1 year multidisciplinary organized weight reducing attempts with less than 5% weight loss
  • Demonstrate decisional capacity

Exclusion Criteria:

  • Psychologically not suitable
  • Pre-menarche or bone age <15 years in boys
  • Obesity associated to other disorders such as hypothyroidism
  • Syndromal disorders such as Prader-Willi syndrome
  • Severe cardiorespiratory impairment (ASA class 3 or higher)
  • Insufficiently fluid in the Dutch language
  • Unwillingness to adhere to follow-up programmes

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Grupo de controle
Control group will receive standard therapy consisting of combined lifestyle interventions.
Experimental: Laparoscopic adjustable gastric band
Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.
Control group will receive standard therapy consisting of combined lifestyle interventions.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Weight
Prazo: 6 months
Weight loss, excess weight loss and loss of excess BMI.
6 months
Weight
Prazo: 12 months
Weight loss, excess weight loss and loss of excess BMI.
12 months
Weight
Prazo: 24 months
Weight loss, excess weight loss and loss of excess BMI.
24 months
Weight
Prazo: 36 months
Weight loss, excess weight loss and loss of excess BMI.
36 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Body composition
Prazo: 12 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
12 months
Pubertal development
Prazo: 6 months
Follow-up of hormonal status and Tanner stages.
6 months
Metabolic and endocrine changes
Prazo: 6 months
6 months
Inflammatory status
Prazo: 6 months
Measurement of serum inflammatory markers.
6 months
Cardiovascular abnormalities
Prazo: 6 months
6 months
Non-alcoholic fatty liver disease
Prazo: 6 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
6 months
Quality of life changes
Prazo: 6 months
6 months
Behaviour changes
Prazo: 6 months
Measuring impulsivity and positive reward dominance with a computer task.
6 months
Operative complications
Prazo: up to 36 months
Early and late complications are being monitored
up to 36 months
Effects on sleep architecture
Prazo: 6 months
6 months
Brain development
Prazo: 6 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
6 months
Body composition
Prazo: 24 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
24 months
Body composition
Prazo: 36 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
36 months
Pubertal development
Prazo: 12 months
Follow-up of hormonal status and Tanner stages.
12 months
Pubertal development
Prazo: 24 months
Follow-up of hormonal status and Tanner stages.
24 months
Pubertal development
Prazo: 36 months
Follow-up of hormonal status and Tanner stages.
36 months
Metabolic and endocrine changes
Prazo: 12 months
12 months
Metabolic and endocrine changes
Prazo: 24 months
24 months
Metabolic and endocrine changes
Prazo: 36 months
36 months
Inflammatory status
Prazo: 12 months
Measurement of serum inflammatory markers.
12 months
Inflammatory status
Prazo: 24 months
Measurement of serum inflammatory markers.
24 months
Inflammatory status
Prazo: 36 months
Measurement of serum inflammatory markers.
36 months
Cardiovascular abnormalities
Prazo: 12 months
12 months
Cardiovascular abnormalities
Prazo: 24 months
24 months
Cardiovascular abnormalities
Prazo: 36 months
36 months
Non-alcoholic fatty liver disease
Prazo: 12 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
12 months
Non-alcoholic fatty liver disease
Prazo: 24 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
24 months
Non-alcoholic fatty liver disease
Prazo: 36 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
36 months
Quality of life changes
Prazo: 12 months
12 months
Quality of life changes
Prazo: 24 months
24 months
Quality of life changes
Prazo: 36 months
36 months
Effects on sleep architecture
Prazo: 12 months
12 months
Effects on sleep architecture
Prazo: 24 months
24 months
Effects on sleep architecture
Prazo: 36 months
36 months
Behaviour changes
Prazo: 12 months
Measuring impulsivity and positive reward dominance with a computer task.
12 months
Behaviour changes
Prazo: 24 months
Measuring impulsivity and positive reward dominance with a computer task.
24 months
Behaviour changes
Prazo: 36 months
Measuring impulsivity and positive reward dominance with a computer task.
36 months
Brain development
Prazo: 12 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
12 months
Brain development
Prazo: 24 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
24 months
Brain development
Prazo: 36 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
36 months
Physical activity
Prazo: 6 months
Assessment of physical activity using a questionnaire and an accelerometer.
6 months
Physical activity
Prazo: 12 months
Assessment of physical activity using a questionnaire and an accelerometer.
12 months
Physical activity
Prazo: 24
Assessment of physical activity using a questionnaire and an accelerometer.
24
Physical activity
Prazo: 36 months
Assessment of physical activity using a questionnaire and an accelerometer.
36 months
Behavior towards food
Prazo: 6 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
6 months
Behavior towards food
Prazo: 12 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
12 months
Behavior towards food
Prazo: 24 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
24 months
Behavior towards food
Prazo: 36 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
36 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: LWE van Heurn, Professor, Maastricht University Medical Center
  • Investigador principal: Yvonne Roebroek, PhD Student, Maastricht University Medical Center
  • Investigador principal: Givan F Paulus, PhD Student, Spaarne Gasthuis, Haarlem

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de dezembro de 2011

Conclusão Primária (Antecipado)

1 de dezembro de 2022

Conclusão do estudo (Antecipado)

1 de dezembro de 2022

Datas de inscrição no estudo

Enviado pela primeira vez

22 de julho de 2010

Enviado pela primeira vez que atendeu aos critérios de CQ

29 de julho de 2010

Primeira postagem (Estimativa)

30 de julho de 2010

Atualizações de registro de estudo

Última Atualização Postada (Real)

26 de agosto de 2021

Última atualização enviada que atendeu aos critérios de controle de qualidade

25 de agosto de 2021

Última verificação

1 de agosto de 2021

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • NL26279.068.09

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever